• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Imugene [ASX:IMU] Shares Rise as Management Seeks to Reassure Shareholders

Like 0

By Kiryll Prakapenka, Monday, 23 May 2022

Australian immune-oncology stock Imugene [ASX:IMU] released a letter this morning addressing shareholder discontent at the recent share price decline.

Australian immune-oncology stock Imugene [ASX:IMU] released a letter this morning addressing shareholder discontent at the recent share price decline.

In late afternoon trade on Monday, IMU shares were up 10%.

The shareholder letter comes after Imugene shed 45% in the last 12 months.

Will management’s optimism about Imugene’s prospects assuage investor concerns?

ASX:IMU stock prices

Source: Tradingview.com

IMU’s letter to shareholders

In a joint statement, Imugene CEO Leslie Chong, and executive chairman Paul Hopper, addressed shareholders about Imugene’s recent share price performance.

In a nutshell, the executives think Imugene is still well-placed, with a ‘rich pipeline and prospects’.

Imugene endeavoured to assure shareholders, claiming it’s ‘as strong as it has ever been in its history’.

Despite this strength, Imugene’s management admitted it was sailing through turbulent seas.

In fact, Imugene reeled off some statistics, showing that since December 2021, biotech shares have ‘fallen dramatically’.

Citing figures from Bloomberg, Imugene reported that ‘April was the worst month on record for US biotechs since at least 1997’.

The biotech sector fell 65% from a peak registered in February 2021.

Despite the souring sentiment for the sector, Imugene remains upbeat.

Why?

In its own words, Imunege management noted:

‘In reality, things have only improved from our share price peak last year. Allow us to remind you about the company you are a shareholder in. Imugene is as strong as it has ever been as we continue to make good progress.

  • We have $100 million in cash making us one of the most financially secure biotechs on the ASX
  • We have 3 unique platform technologies supporting 6 unique assets – onCARlytics, CHECKvacc; PD1-Vaxx; CF33 (VAXINIA) & HER-Vaxx
  • Within 12 months we expect to have ~10 clinical studies supported by 5-6 FDA IND’s
  • Our drugs are targeting more than 10 disease areas
  • We have 2 supply agreements with leading pharmaceutical companies
  • We have 2 industry/scientific collaborations’

Imugene also addressed the recent cancellation of a supply agreement with Merch & Co.

Imugene labelled the reaction to the cancellation as a ‘storm in a teacup’:

Three novel technology platforms

Source: Imugene

Imugene share price outlook and seeking bargains in today’s market

In its most recent half-yearly results, Imugene reported a net loss of $14.8 million, up from $6 million in the prior corresponding half.

Proceeds from issuing new shares during the half propped up Imugene’s cash holdings, with the biotech stock ending the period with $118.4 million in cash and cash equivalents.

Today’s jittery climate spooked by inflation and rising rates doesn’t help sectors like the biotech industry, whose stocks often operate without revenues for years.

Rising rates make distant profits in research companies less appealing.

But that’s not to say that rising rates affect all stocks equally.

The current climate offers opportunities for the savvy investor willing to zag while others zig.

But how best to identify the opportunities?

Our expert, Callum Newman, recently released a report on ‘left-for-dead’ stocks that could rebound in a big way.

You can find out more about Callum’s three ‘grave-dancer’ stocks here.

Regards,

Kiryll Prakapenka,
For Money Morning

 

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
    By Charlie Ormond

    Markets have always reflected this chaotic behaviour, but today’s markets operate in an environment fundamentally transformed by social media.

  • The latest Closing Bell is available now
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss gold, oil, real estate…plus a stock to watch. Tune in now!

  • Thorium: One Step Closer to China’s Energy Fortress
    By James Cooper

    Forget AI, the biggest breakthrough of this century will revolve around ENERGY. And the commercialisation of Thorium reactors could be at the heart. Read on to find out why China could be about to make history.

Primary Sidebar

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
  • The latest Closing Bell is available now
  • Thorium: One Step Closer to China’s Energy Fortress
  • The famous yield curve: buy or sell signal? You decide…
  • How Australians voted for a great wealth redistribution

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988